NCT05244070View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Leukemia, Lymphocytic, Chronic, B-CellLymphoma
Interventions
DRUG

BMS-986403

Specified dose on specified days

DRUG

Fludarabine

Specified dose on specified days

DRUG

Cyclophosphamide

Specified dose on specified days

Trial Locations (9)

28040

Local Institution, Madrid

35249

Local Institution - 0005, Birmingham

37007

Local Institution, Salamanca

43210

Local Institution - 0009, Columbus

91010

Local Institution - 0016, Duarte

02114

Local Institution - 0007, Boston

07601

Local Institution - 0026, Hackensack

98109-4433

Local Institution - 0002, Seattle

08035

Local Institution - 0024, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05244070 - A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter